EUCTR2011-000618-20-ES进行中（未招募）不适用
A phase III trial evaluating both erlotinib and chemoradiation as adjuvant treatment for patients withresected head of pancreas adenocarcinoma.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- EORTC
- 入组人数
- 950
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy. Patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible
- •The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved. The pathology report must include documentation of the margin status and the size of the tumor. The pathology report nmust also include the status of the three major margins?bile duct, pancreatic parenchyma, and retroperitoneal (uncinate).
- •2. Interval between definitive tumor-related surgery and 1st step registration between 21-56 days.
- •3 Patients will be staged according to the 6th edition AJCC staging system with pathologic stage T1-3, N0-1, M-0 being eligible.
- •4. Age ? 18.
- •5 Zubrod performance status 0 or 1.
- •6 Complete history and physical examination including weight and Zubrod status within 31 days of study entry.
- •7. Before starting therapy the patient should be able to maintain adequate oral nutrition of ? 1500 calories estimated caloric intake per day and be free of significant nausea and vomiting.
- •8. CBC/differential obtained within 21 days of registration on study, with adequate bone marrow function defined as follows:
- •- Absolute neutrophil count (ANC) ? 1,500 cells/mm3
- •- Platelets ? 100,000 cells/mm3
- •- Hemoglobin ? 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ? 8.0 g/dl is acceptable.)
- •9 Post resection serum CA19-9 ? 180 units/mL within 21 days of registration on study.
- •10 Patients must have:
- •- Serum total bilirubin ? twice the institutional upper limit of normal within 21 days of registration on study.
- •- Creatinine levels ? twice the institutional upper limit of normal within 21 days of registration on study.
- •- SGOT must be ? 2.5 x the institutional upper limit of normal within 21 days of registration on study.
- •11 Negative serum pregnancy test for women of childbearing potential within 14 days of study registration.
- •12 Abdominal/pelvic CT scan with contrast and chest CT/x-ray (CT of chest preferred) within 31 days of registration on study. Patients allergic to IV contrast can have MRI of the abdomen/pelvis instead.
- •13 Signed study-specific informed consent
- •14 Consultation, agreement, and documentation in the patient?s chart by a radiation oncologist that patient is suitable to receive radiotherapy per this protocol.
- •15 Women of childbearing potential and male participants must practice adequate contraception.
- •16 Patients with active HIV infection are eligible if their CD4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of HAART is allowed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 900
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1.Patients with non-adenocarcinomas, adenosquamous carcinomas, islet cell (neuroendocrine) tumors, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas.
- •2 Patients managed with a total pancreatectomy, a distal pancreatectomy, or central pancreatectomy.
- •3 Prior systemic chemotherapy for pancreas cancer; note that prior chemotherapy for a different cancer is allowable.
- •4 Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- •5 Previous history of invasive malignancy (except non-melanoma skin cancer) unless the patient as been disease free for at least 2 years prior to study entry (Patients with a previous history of carcinoma in situ are eligible.
- •6 Severe, active co-morbidity, defined as follows:
- •-Unstable angina and/or congestive heart failure requiring hospitalization within the last 6
- •-Transmural myocardial infarction within the 3 months of study registration
- •- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
- •- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- •7 Pregnant or lactating women
- •8 Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
- •9 If surgical margin status cannot be determined after consultation with the operating surgeon and the institutional pathologist, the patient will be ineligible.
研究者
相似试验
已完成
3 期
Randomized phase III study comparing erlotinib plus bevacizumab to erlotinib alone in patients with previously untreated non-small cell lung cancer harboring EGFR mutation (NEJ026)Advanced non-squamous non-small cell lung cancerJPRN-UMIN000017069orth East Japan Study Group (NEJSG)214
进行中（未招募）
1 期
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 15.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-HUETOP (European Thoracic Oncology Platform)500
进行中（未招募）
1 期
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-IEETOP (European Thoracic Oncology Platform)500
进行中（未招募）
1 期
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-DEETOP (European Thoracic Oncology Platform)80
进行中（未招募）
不适用
Testing of the two drugs erlotinib and docetaxel in lung cancer patients who have been classified regarding their outlook using VeriStrat®.Squamous cell non-small cell lung cancer in patients who have failed first-line platinum-based doublet chemotherapy.MedDRA version: 14.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001896-35-NLETOP (European Thoracic Oncology Platform)500